Piceatannol,a natural trans-stilbene compound,inhibits human glyoxalase I |
| |
Authors: | Ryoko Takasawa Haruka Akahane Hikari Tanaka Nami Shimada Takayuki Yamamoto Hiroko Uchida-Maruki Masahiko Sai Atsushi Yoshimori Sei-ichi Tanuma |
| |
Institution: | 1. Faculty of Pharmaceutical Sciences, Tokyo University of Science, 2641 Yamazaki, Noda, Chiba 278-8510, Japan;2. Genome & Drug Research Center, Tokyo University of Science, 2641 Yamazaki, Noda, Chiba 278-8510, Japan;3. Health Science Research Center, Morinaga & Co., Ltd., 2-1-1 Shimosueyoshi, Tsurumi-ku, Yokohama 230-8504, Japan;4. Institute for Theoretical Medicine, Inc., Tokyo Institute of Technology Yokohama Venture Plaza W101, 4259-3 Nagatsuda, Midori, Yokohama, Kanagawa 226-8510, Japan |
| |
Abstract: | Human glyoxalase I (GLO I), a rate-limiting enzyme for detoxification of methylglyoxal (MG), a by-product of glycolysis, is known to be a potential therapeutic target for cancer. Here, we searched new scaffolds from natural compounds for designing novel GLO I inhibitors and found trans-stilbene scaffold. We examined the inhibitory abilities to human GLO I of commercially available trans-stilbene compounds. Among them, piceatannol was found to have the most potent inhibitory activity against human GLO I. Piceatannol could inhibit the proliferation of human lung cancer NCI-H522 cells, which are dependent on GLO I for survival, in a dose- and time-dependent manner. In addition, piceatannol more significantly inhibited the proliferation of NCI-H522 cells than that of NCI-H460 cells, which are less dependent on GLO I. Importantly, overexpression of GLO I in NCI-H522 cells resulted in less sensitive to the antiproliferative activity of piceatannol. Taken together, this is the first report demonstrating that piceatannol inhibits GLO I activity and the GLO I-dependent proliferation of cancer cells. Furthermore, we determined a pharmacophore for novel inhibitors of human GLO I by computational simulation analyses of the binding mode of piceatannol to the enzyme hot spot in the active site. We suggest that piceatannol is a possible lead compound for the development of novel GLO I inhibitory anticancer drugs. |
| |
Keywords: | Glyoxalase I Inhibitor Stilbenes Piceatannol Anticancer GLO I Glyoxalase I BBGC GSH glutathione HIPC-GSH NSCLC Non-small cell lung cancer PDB Protein Data Bank VS virtual screening |
本文献已被 ScienceDirect 等数据库收录! |
|